Literature DB >> 1804815

Phase I-II study of high-dose etoposide in patients with refractory breast cancer.

G Fraschini1, F A Holmes, L Esparza, R L Theriault, A U Buzdar, G N Hortobagyi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1804815     DOI： 10.1007/BF00183583

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  6 in total

1.  Comprehensive criteria for assessing therapy-induced toxicity.

Authors:  J A Ajani; S R Welch; M N Raber; W S Fields; I H Krakoff
Journal:  Cancer Invest       Date:  1990       Impact factor: 2.176

2.  Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research.

Authors:  G Cocconi; G Bisagni; M Bacchi; C Boni; R Bartolucci; G Ceci; M A Colozza; V De Lisi; R Lottici; A M Mosconi
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

3.  High-dose etoposide (VP-16) in small-cell lung cancer.

Authors:  F A Greco; D H Johnson; K R Hande; L L Porter; J D Hainsworth; S N Wolff
Journal:  Semin Oncol       Date:  1985-03       Impact factor: 4.929

4.  Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support.

Authors:  F R Dunphy; G Spitzer; A U Buzdar; G N Hortobagyi; L J Horwitz; J C Yau; J A Spinolo; S Jagannath; F Holmes; R O Wallerstein
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

5.  Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.

Authors:  F C Schell; H Y Yap; G N Hortobagyi; B Issell; L Esparza
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  VP16-213 and cyclophosphamide in advanced breast cancer. A phase II study.

Authors:  J Estapé; L Cirera; A Millá; F Doncel
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333
  6 in total
  1 in total

1.  Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association.

Authors:  G W Thomas; H B Muss; D V Jackson; J McCulloch; W Ramseur; J McFarland; H Hoen; M Pavy; R Heath
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.